Because of the hypoxic nature of tumors, cancer cells have elevated levels of NRF2 signaling well above the basal level found in normal cells [26,27], and up to 30% of lung cancers acquire a mutation within the tumor cells which results in constitutive NRF2 pathway activation [28]. This evidence concerns the gene NFE2L2 and cancer.